OHSU Knight Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, OHSU Knight Cancer Institute sits in the top decile of US sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count).
OHSU Knight Cancer Institute: 211 sponsored US clinical trials, 35 recruiting.
OHSU Knight Cancer Institute sponsors 211 registered US clinical trials on ClinicalTrials.gov, 35 of them currently recruiting, and 94 completed. 5 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 6 trials.
Top-decile sponsor footprint
OHSU Knight Cancer Institute ranks in the top decile of sponsors by registered trial count (#150 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
94 of 149 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
211 total, page 1 of 5
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
NCT04529044
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
NCT07405086
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
NCT07548983
A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT07651358
GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer
NCT07504835
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
NCT07089940
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
NCT07228273
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
NCT06895473
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
NCT06357676
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
NCT06784167
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
NCT06504459
Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial
NCT06673095
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
NCT06357182
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
NCT05705492
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
NCT05919329
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
NCT06067438
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
NCT06249191
CREATE: Art for Children With Cancer
NCT06342453
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
NCT06320405
Use Of Indocyanine Green In Pancreas Surgery
NCT06084013
EMBRACE: Exercising Together
NCT06049355
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
NCT06011499
Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas
NCT05937776
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT05943496
Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer
NCT06562777
Impact of Dietary Fiber Supplementation on Colonic Microbiome
NCT05643859
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool
NCT05407168
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
NCT04872790
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
NCT05081024
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT04659616
Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT04494945
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
NCT04005690
Feasibility of FMISO in Brain Tumors
NCT03649880
War on Melanoma™ Public Health & Education Campaign
NCT04611568
Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
NCT03270059
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
NCT06630325
BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy
NCT06335966
Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma
NCT06157099
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
NCT05722925
Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation
NCT04969978
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
NCT05396859
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT05034627
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
NCT04850599
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
NCT04993313
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
NCT04539808
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
NCT04251715
Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer
NCT04946279
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
NCT04267887
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
NCT04104139
Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma
NCT03960177
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 73 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the OHSU Knight Cancer Institute pipeline
35 recruiting of 211 indexed (17% open); 94 completed (45%).
Phase mix: 5 late (III/IV) vs 114 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
OHSU Knight Cancer Institute: open-pipeline peers nationwide
Peers matched on 211 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
OHSU Knight Cancer Institute sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 211 trials (± recruiting share)
- MedImmune · 210 trials · 0% recruiting
- University of Louisville · 217 trials · 21% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Rush University Medical Center · 17% recruiting · 320 trials
- Massachusetts General Hospital · 17% recruiting · 2,032 trials
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
Related
What to do with this OHSU Knight Cancer Institute page
211 registered trials is a research-attention snapshot, not an endorsement of OHSU Knight Cancer Institute or any single study.
- 35 of OHSU Knight Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition OHSU Knight Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
OHSU Knight Cancer Institute pipeline card: 211 registered trials from official public datasets.Report a data error.